Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation

Ryan C. Fields, Ankit Bharat, Nancy Steward, Aviva Aloush, Brian F. Meyers, Elbert P. Trulock, William C. Chapman, G. Alexander Patterson, Thalachallour Mohanakumar

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

BACKGROUND. The long-term function of lung transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS). Due to lack of specific markers, BOS is diagnosed clinically. Because there is strong evidence that alloimmunity plays a significant role in the pathogenesis of BOS, we investigated whether soluble CD30 (sCD30), a T-cell activation marker, would correlate with BOS. METHODS. Sera collected serially from BOS+ (n=20) and matched BOS- (n=20) lung transplant (LT) patients were analyzed for sCD30 by enzyme-linked immunosorbent assay. Pretransplant sera and sera from normal donors were also analyzed. RESULTS. PreLT levels were comparable to normal subjects. However, posttransplant there was a significant elevation in sCD30 levels during BOS development in all BOS+ patients, compared to BOS- (mean 139.8±10.7 vs. 14.8±2.7 U/ml, P<0.001). sCD30 levels declined in the BOS+ patients but were still elevated compared to BOS- (48.52±5.04 vs. 7.19±2.9, P<0.0001). CONCLUSIONS. We conclude that sCD30 may represent a novel marker to monitor the development of BOS.

Original languageEnglish
Pages (from-to)1596-1601
Number of pages6
JournalTransplantation
Volume82
Issue number12
DOIs
StatePublished - Dec 1 2006

Keywords

  • Bronchiolitis obliterans
  • Chronic rejection
  • Lung transplantation
  • Markers of rejection
  • sCD30

Fingerprint Dive into the research topics of 'Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation'. Together they form a unique fingerprint.

  • Cite this